- Home
- Publications
- Publication Search
- Publication Details
Title
Avelumab: A Review in Metastatic Merkel Cell Carcinoma
Authors
Keywords
-
Journal
Targeted Oncology
Volume 13, Issue 3, Pages 409-416
Publisher
Springer Nature
Online
2018-05-24
DOI
10.1007/s11523-018-0571-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
- (2018) Karen Kelly et al. CANCER
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma
- (2018) Sandra P. D’Angelo et al. JAMA Oncology
- Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
- (2018) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs
- (2017) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma
- (2017) Paul Nghiem et al. Future Oncology
- Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
- (2017) C Lance Cowey et al. Future Oncology
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy
- (2017) Teresa Amaral et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
- (2017) Jürgen C. Becker et al. Oncotarget
- Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
- (2017) Peng-Fei Wang et al. Frontiers in Pharmacology
- Merkel cell carcinoma
- (2017) Jürgen C. Becker et al. Nature Reviews Disease Primers
- Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System
- (2016) Kelly L. Harms et al. ANNALS OF SURGICAL ONCOLOGY
- Merkel Cell Carcinoma Therapeutic Update
- (2016) Nicole M. Cassler et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses
- (2016) Patrick J. Medina et al. PHARMACOTHERAPY
- Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
- (2016) Rika Fujii et al. Oncotarget
- Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
- (2016) Jayasri G. Iyer et al. Cancer Medicine
- Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline
- (2015) Celeste Lebbe et al. EUROPEAN JOURNAL OF CANCER
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
- (2013) O. K. Afanasiev et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
- (2013) E. J. Lipson et al. Cancer Immunology Research
- The Role of the Immune Response in Merkel Cell Carcinoma
- (2013) Pierre Triozzi et al. Cancers
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now